Earnings Call · Q1 FY2023·2023-04-29

Q1 23EPS 0.00%·Rev n/aQ4 22EPS -100.00%*·Rev n/aQ3 22EPS -3.45%·Rev n/aQ2 22EPS +14.53%·Rev n/a⚠ consensus missing

Indivior Pharmaceuticals, Inc. INDV

Jason Thompson — Investor Relations or Communications (inferred from call introduction)

Mark Crossley — Chief Executive Officer

Ryan Preblick — Chief Financial Officer

no move data

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more INDV calls or request research access.

More INDV calls Browse calls Request research access